Clinical Trial Update: Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of tipifarnib and naxitamab for relapsed/refractory neuroblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Naxitamab (naxitamab)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING